Blackstone Inc.
Blackstone Inc. (BX) Stock News
The latest BX headlines and market coverage — 5 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
MBX Biosciences announced positive one-year data from its open-label extension study of canvuparatide, a once-weekly PTH replacement therapy for chronic hypoparathyroidism. The drug maintained a 57% responder rate at one year with a 90% retention rate, demonstrated sustained benefits in calcium homeostasis, kidney function, and bone metabolism, and showed no new safety signals. The company remains on track to initiate Phase 3 pivotal trials in Q3 2026.
- GlobeNewswire Inc.·
KoinBX, FIU-Registered and Trusted by 1.5 Million Users, Drives Accessible Crypto Trading in India
Coinbase has expanded its India operations by enabling direct INR deposits and withdrawals through IMPS, alongside spot trading and perpetual futures products. KoinBX, a FIU-registered Indian cryptocurrency exchange with 1.5 million users, welcomed the expansion as a positive indicator of India's growing importance in the global digital asset ecosystem. The move is expected to strengthen competition and improve liquidity, trading infrastructure, and user experience across the sector.
- Benzinga·
Why Is U-BX Technology Stock Falling After Hours Today?
U-BX Technology (NASDAQ: UBXG), a China-based AI-driven insurance technology company, announced a 1-for-25 reverse stock split effective Friday. The stock fell 15.6% in after-hours trading to $0.11 following the announcement. The reverse split will combine every 25 shares into one share, reducing outstanding Class A shares from 37.79 million to 1.51 million. The stock has plunged over 96% in the past 12 months and is trading near its 52-week low.
- GlobeNewswire Inc.·
U-BX Technology Ltd. Announces Effective Date of Reverse Stock Split
U-BX Technology Ltd. (NASDAQ: UBXG), an AI-driven insurance technology provider, announced a 1-for-25 reverse stock split effective May 22, 2026. The split will reduce outstanding class A shares from approximately 37.79 million to 1.51 million and class B shares from 7.66 million to 0.31 million. The ratio was determined by the Board of Directors following shareholder approval at the November 2025 annual meeting.
- GlobeNewswire Inc.·
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
MBX Biosciences announced preliminary Phase 1 data for MBX 4291, a GLP-1/GIP co-agonist prodrug showing 7% mean weight loss at 8 weeks with good tolerability and potential for once-monthly dosing. The company also nominated MBX 5765, a novel four-agonist candidate for obesity, and achieved proof of concept for imapextide in post-bariatric hypoglycemia, though will not pursue further Phase 2b development of the latter to prioritize resources.